Step 3 of 12: Health Economics and Reimbursement Strategy
- 3 days ago
- 11 min read
There’s a moment that happens in almost every hospital sales process.
The physician champion finishes explaining why your technology matters clinically. Everyone nods politely. The room feels optimistic. You start mentally calculating future revenue.
Then somebody from finance asks:
“How does this impact the budget?”
And suddenly the entire energy changes.
Because now nobody cares how innovative the technology is. They care whether the economics survive scrutiny from people whose full-time job is preventing hospitals from lighting money on fire in exciting new ways.
And the way you answer that question matters more than most founders realize.
Because that moment determines whether your company gets viewed as a credible long-term partner or just another startup with a good demo and a weak business case. Hospitals can tolerate uncertainty. What they do not tolerate well is financial ambiguity delivered with excessive confidence. That combination has probably funded at least three administrator vacations and a few early vendor graveyards.
This is Step 3 of the recovery program, and honestly, it’s probably the step that saves companies the most money long term.
The Three Ways Companies Financially Kill Themselves
Most MedTech companies don’t die because the technology is bad.
A shocking number die because the economics were either weak, vague, or completely made up.
Usually one of three things is happening.
Assuming reimbursement is somebody else’s problem
Founders love saying things like:
“We’re cash pay."
“We don’t need a CPT code.” “We’re just improving workflow.” “This is operational, not reimbursement-driven.”
Maybe. Maybe not.
Even if your product does not depend on a dedicated reimbursement pathway, reimbursement still shapes the financial conversation around your technology. It affects service line budgets, procedural profitability, staffing logic, procurement decisions, and whether administration sees your product as an investment or an expense they now have to explain at budget review.
And the second you walk into a room with people who do understand reimbursement deeply, it becomes very obvious very quickly if you don’t.
Healthcare has a unique ability to expose shallow thinking in real time. It’s honestly kind of impressive.
Building an ROI story held together by hope and PowerPoint animations
This one kills credibility fast.
You stack six assumptions on top of each other, tell the hospital they’ll save $2.7 million annually, and suddenly the room gets very quiet in the worst possible way.
Hospital administrators have seen every version of this deck already. Most of them can smell fake economics by slide three.
Real economic modeling is boring. That’s usually how you know it’s real.
One measurable lever at a time:
Time savings
Staffing changes
Reduced complications
Fewer revisits
Higher throughput
Lower LOS
Reduced readmissions
Better room utilization
That’s it. KISS = Keep It Simple, Stupid.
Ground it in things you can actually defend. Build slowly. Use real operational assumptions. Show your math.
“Improves efficiency” is marketing language.
“At your current volume, this reduces approximately 19 staff hours per month” is a conversation.
Those are not the same thing.
Not understanding who you’re talking to
Economic storytelling changes depending on the room.
This is where founders accidentally give investor presentations to hospital operators and wonder why nobody cares.
There are really two major ways to frame economics:
Top-down economics
This is the macro story.
Market size. Disease burden. System-wide costs. Population impact.
This is investor language. CFO language. Strategy language.
Example:
“Hospital-acquired complications in this category cost the U.S. healthcare system billions annually. Based on your procedural volume, reducing incidence by X% translates to approximately Y in avoided annual cost.”
That helps contextualize why the problem matters.
Bottom-up economics
This is operational reality.
Minutes per case. Staff touches. Disposable usage. Turnover time. Clinic flow. OR utilization.
This is VAC language. Service line language. Department administrator language.
Example:
“You currently need three staff members for 45 minutes. This reduces that to two staff for 28 minutes. At your procedural volume, that recovers roughly X hours monthly.”
Same product. Same value proposition.
Completely different conversation.
If you don’t know which version to lead with, you’re probably not ready for the meeting yet.
Quick tip: Try to enable yourself to be a fly in the room and observe to give real data to use as leverage. This is a pro move.
Prospective vs. Retrospective Data: Know What You’re Actually Buying
Prospective data is the gold standard.
You define endpoints ahead of time. You control how the data is collected. You standardize inclusion criteria, outcome measures, timelines, and methodology before the first patient is even enrolled. The entire study is intentionally built around a specific hypothesis or clinical question you are trying to prove, disprove, or better understand.
That structure matters.
Prospective studies carry more weight because the rigor is built into the design itself. You're reducing bias upfront instead of trying to untangle it afterward. Payers trust it more. Procurement committees trust it more. Reviewers trust it more.
The downside?
Time. Money. Patience. Human suffering. The occasional sacrifice.
Prospective studies are expensive and slow, and every month you spend waiting for pristine data is another month your runway keeps shrinking quietly in the background like a horror movie subplot nobody wants to acknowledge.
Retrospective data moves faster because the information already exists. You're looking backward at real-world cases, chart reviews, registries, or historical workflows and trying to identify trends, relationships, operational insights, or directional signals from what already happened.
That can still be incredibly valuable, especially early.
But retrospective evidence needs to be presented carefully.
You're often making inferences based on observed patterns rather than proving causation outright. A lot of founders unintentionally blur that line. They present retrospective observations with the confidence level of prospective outcomes, and sophisticated buyers catch it immediately.
Usually within about five minutes. Faster if legal or compliance showed up to the meeting.
Neither approach is inherently wrong.
The mistake is pretending retrospective evidence carries the same weight as prospective evidence, or delaying all commercial conversations for years because you’re waiting for “perfect” data when strong retrospective evidence could already be opening doors.
And here’s the part founders underestimate constantly:
Data is not free.
Chart reviews cost money. Registries cost money. Real-world evidence collection costs money.
Statistical support costs money. Site management costs money.
Every single data point has a price tag attached to it somewhere.
Before you spend money generating evidence, know exactly:
What question it answers
What claim it supports
What audience it matters to
What level of rigor it actually carries
Because overselling weak evidence is worse than having no evidence at all.
Once buyers stop trusting your claims, that reputation spreads surprisingly fast. Hospitals talk. Procurement talks. Surgeons talk. Industry people gossip like exhausted middle schoolers in Patagonia vests.
There's a time and place for both. Choose wisely depending on your stage.
Your Pricing Strategy Is Part of Your Clinical Story
Pricing in MedTech gets discussed like a finance exercise when it’s actually a positioning exercise.
Your price is a claim.
If you charge premium pricing, you are implicitly claiming premium value. Which means someone is eventually going to ask you to prove it.
And if the economics and evidence don’t support the number, the deal usually dies long before you ever hear the official “no.”
The chilling effect is real.
Price too aggressively too early and you don’t just lose that account. You create skepticism that follows you into future conversations.
Supply chain teams compare notes. Administrators move hospitals. VAC members know each other. Healthcare is simultaneously enormous and weirdly small. Everyone is incentivized in different ways.
If your pricing doesn’t align with what your data actually proves, people start questioning whether you understand your own market.
That perception is hard to recover from.
The rule is simple:
The value delivered needs to feel obviously greater than the cost.
Not slightly greater. Obviously greater.
And you need evidence behind it:
Time studies
Operational metrics
Pilot data
Clinical testimonials
Before-and-after workflows
Reference accounts
Show hospitals their own economics reflected back to them. Again, use the KISS method (Keep It Simple, Stupid).
“At your annual case volume, this likely recovers approximately X OR hours per year.”
That lands.
“Our platform streamlines efficiency.”
That sounds like a LinkedIn post written during a layover.
Conservative Early Pricing Is Not Weakness
A lot of founders emotionally attach pricing to self-worth.
They spent years building something difficult and want immediate market validation.
Unfortunately, the market does not care how hard your journey was. The market cares whether adopting your product creates less risk than ignoring it.
Early pricing strategy is often about reducing friction, not maximizing margin.
Getting your first real reference sites matters more than squeezing every dollar out of the first contract.
Because early sites give you:
Operational data
Testimonials
Workflow validation
Economic evidence
Reference accounts
Publications
Case studies
That stuff is worth a fortune early on.
But here’s the trap:
If you structure pilot agreements poorly, your “temporary” discount becomes your permanent commercial reality.
Now you’re stuck trying to explain why pricing is increasing after two years of conditioning the customer to expect otherwise.
That conversation gets uglier the longer you wait.
Version Your Product Like You Actually Planned Ahead
V1 gets you in the door.
V2 is supposed to justify expanded pricing.
But a lot of companies get lazy here.
They add a minor feature, rename the platform, bump pricing, and act shocked when procurement pushes back.
The relationship between product evolution and pricing evolution needs to be intentional from the beginning.
Ask yourself:
What does V2 solve that V1 doesn’t?
What operational burden disappears?
What measurable value improves?
What new workflow becomes possible?
What economic lever changes?
If you can’t answer those clearly before V1 even launches, your future pricing conversations are going to get uncomfortable fast.
This is not just product strategy.
It’s commercial strategy.
Capital vs Subscription vs Per-Use Actually Matters
This decision shapes way more than founders think.
Capital purchases move through completely different hospital approval pathways than operating expenses.
Subscription models create different budgeting optics than procedural fees.
Per-use pricing can accelerate adoption because hospitals only pay when they use it, which sounds great until your investors realize your revenue predictability now resembles a weather forecast in Florida.
There’s no universal answer.
There’s just the right answer for your product, buyer, adoption model, and company stage.
And getting it wrong creates problems that extend way beyond pricing itself.
Honestly, pricing strategy in MedTech is deep enough to deserve its own entire series. We’ll get there eventually because apparently none of us are escaping healthcare economics anytime soon.
Reimbursement Is Messier Than People Pretend
Getting a brand-new CPT code is not some quick administrative process.
It’s political. Expensive. Slow. Complex. There are entire careers built around navigating it.
And deservedly so.
That’s not my lane, and I’d rather tell you that directly than cosplay poorly as a reimbursement attorney on the internet.
What I will tell you is this:
No dedicated reimbursement pathway does not automatically mean no commercial pathway.
Sometimes adjacent reimbursement structures already exist.
Sometimes workflow positioning matters more than coding.
Sometimes the smarter move is competing inside an already-funded category instead of spending five years burning runway chasing a code.
Companies that think strategically about reimbursement early usually survive longer than companies treating reimbursement like a post-clearance surprise.
A few pathways worth knowing exist:
NTAP - New Technology Add-On Payment
The New Technology Add-on Payment program through CMS can provide additional reimbursement to hospitals using qualifying new technologies beyond the standard DRG payment structure.
The goal is reducing financial disincentives for adopting genuinely novel inpatient technology.
Not everybody qualifies. The process is serious work. But if your technology is truly differentiated and inpatient-focused, you should at least understand the pathway before assuming it’s irrelevant.
RAPID - Regulatory Alignment for Predictable and Immediate Device
As of 2026, this one deserves attention.
The RAPID pathway is intended to better synchronize CMS coverage timing with FDA review so reimbursement conversations don’t lag years behind clearance decisions.
Historically, some breakthrough technologies waited absurdly long periods for meaningful Medicare coverage after FDA authorization.
For the right company, RAPID could materially change commercialization timelines.
The details are still evolving, but it’s worth watching closely.
Neither of these pathways are things I personally execute.
But both are things founders should absolutely know exist before concluding reimbursement is either impossible or magically guaranteed.
Success Story: HeartFlow - Playing the Long Game Correctly
HeartFlow is one of the better examples of what playing the reimbursement long game actually looks like.
They built an AI-powered cardiac diagnostic platform capable of non-invasively analyzing coronary artery disease. Clinically impressive technology. But the technology itself is not what built the commercial success story. The reimbursement strategy underneath it is where things get genuinely interesting.
Before broad reimbursement existed, HeartFlow started building the economic infrastructure around the product. Provider economics. Imaging center relationships. Payer engagement. Utilization strategy. They understood something a lot of early-stage companies learn too late: there’s a dangerous gap between FDA clearance and scalable adoption, and a lot of companies run out of money in that gap.
Because hospitals do not magically adopt technology just because it works.
There has to be a financial pathway.
And HeartFlow didn’t sit around waiting for CMS to eventually figure it out for them.
In 2018, the AMA established four temporary Category III CPT codes specifically tied to HeartFlow’s FFRct analysis. Category III codes are essentially the proving ground for emerging technologies. They’re designed to track utilization and build evidence for procedures or technologies that are promising but not yet mature enough for permanent reimbursement infrastructure.
Importantly, Category III codes usually do not carry the reimbursement stability or widespread payer support of Category I codes. Many private insurers still treat technologies under them as experimental or investigational.
But that’s not the point.
The point is that they create a measurable utilization trail.
That matters more than founders realize.
HeartFlow used that period strategically. By 2022, there had been 8,665 reported uses under those temporary codes, generating approximately $8.4 million in Medicare spending data. That didn’t happen accidentally. That was deliberate utilization building designed to demonstrate real-world adoption, clinical relevance, and economic activity at scale.
And then comes the part most founders completely underestimate.
HeartFlow did not personally march into the AMA demanding permanent Category I status.
The American College of Cardiology and the Society of Cardiovascular Computed Tomography advocated for it.
That distinction matters enormously.
Professional societies carry serious influence in the coding and reimbursement ecosystem. HeartFlow had spent years cultivating relationships, generating evidence, and building credibility within organized medicine so that when the time came, the specialty societies themselves were willing to push for permanent adoption.
That is not a marketing exercise. That is strategic infrastructure building.
If you’re building an AI-enabled MedTech platform and you are not thinking early about which professional societies could eventually become advocates for your technology, you are ignoring one of the most powerful reimbursement levers available to you.
By January 2024, HeartFlow officially received a permanent Category I CPT code, replacing the temporary Category III structure entirely.
The full journey from early development to permanent reimbursement infrastructure took roughly a decade.
Most startups do not have a decade of runway sitting around waiting for reimbursement maturity, and that’s not really the lesson here anyway.
The lesson is that HeartFlow treated reimbursement as a strategic discipline long before they absolutely needed it. They built clinical evidence intentionally. They built utilization intentionally.
They cultivated payer and society relationships intentionally.
None of this happened accidentally.
And almost none of it started after clearance.
The Bottom Line
Clinicians decide whether your product is clinically valuable.
Finance decides whether it survives.
Build the economic story early. Keep it honest. Keep it simple. Know your audience. Understand the reimbursement environment you’re entering instead of pretending it will magically solve itself later.
Price intentionally.
Structure pilots carefully. Generate evidence that actually supports the claims you’re making.
And remember this:
A hospital does not buy your technology because it’s impressive. It buys because somebody inside the system can defend the decision financially. That’s the game whether founders like it or not.
Next week: Step 4. Productization & Technical Readiness.
The phase where FDA clearance collides headfirst with hospital IT infrastructure and suddenly everyone discovers what “integration” actually means.
👉 Take the U.S. Commercial Readiness Self-Assessment to see how prepared you are.
Curious about the other 11 steps to recovering your medtech business? Click here to learn more!
About the author
Robert Law is the founder of Metamorph MedTech, a go-to-market consulting practice built for medical device and healthcare AI companies that have cleared the FDA and now have to figure out what comes next. With a Kellogg MBA and hands-on experience across surgical robotics, implantable devices, and AI-powered platforms, Robert works in the space where great technology meets commercial reality: health economics, hospital sales strategy, VAC navigation, reimbursement positioning, and the kind of go-to-market infrastructure that turns pilots into revenue. He started Metamorph because too many good technologies were losing to bad commercial strategies, and that bothered him more than he could ignore. Learn more here.
Comments